Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: A prospective clinical trial

Blood

Volumn 122, Issue 5, 2013, Pages 648-657

  Mannucci, Pier Mannuccio ^a   Kempton, Christine ^b   Millar, Carolyn ^c   Romond, Edward ^d   Shapiro, Amy ^e   Birschmann, Ingvild ^f   Ragni, Margaret V ^g   Gill, Joan Cox ^h   Yee, Thynn Thynn ⁱ   Klamroth, Robert ^j   Wong, Wing Yen ^k   Chapman, Miranda ^k   Engl, Werner ^k   Turecek, Peter L ^k   Suiter, Tobias M ^k   Ewenstein, Bruce M ^k  

^a UNIVERSITY OF MILAN   (Italy)

^b EMORY UNIVERSITY   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF KENTUCKY   (United States)

^e INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^k BAXTER HEALTHCARE CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; COLLAGEN; PLASMA DERIVED BLOOD CLOTTING FACTOR 8; PLASMA DERIVED VON WILLEBRAND FACTOR; POLYMER; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT VON WILLEBRAND FACTOR; RECOMBINANT VON WILLEBRAND FACTOR RISTOCETIN COFACTOR; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR BINDING ANTIBODY; RECOMBINANT PROTEIN;

ADULT; ANTIBODY TITER; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEMOSTASIS; HUMAN; HYPERTENSION; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CLEAVAGE; PROTEIN STABILITY; PRURITUS; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; VON WILLEBRAND DISEASE; ADOLESCENT; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84885638015     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-479527     Document Type: Article

References (45)

1. Nichols WC, Ginsburg D. von Willebrand disease. Medicine (Baltimore). 1997; 76(1): 1-20.
2. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000; 84(2): 160-174. (Pubitemid 30601459)
3. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977; 60(2): 390-404. (Pubitemid 8154146)
4. Wise RJ, Dorner AJ, Krane M, Pittman D.D., Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem. 1991; 266(32): 21948-21955. (Pubitemid 121000273)
5. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004; 351(7): 683-694.
6. Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost. 1999; 82(2): 585-591.
7. Mannucci PM, Chediak J, Hanna W., et al.; Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002; 99(2): 450-456. (Pubitemid 34533078)
8. Gill JC, Ewenstein BM, Thompson A.R., Mueller-Velten G, Schwartz BA; Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003; 9(6): 688-695. (Pubitemid 37540809)
9. Federici AB, Baudo F, Caracciolo C., et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia. 2002; 8(6): 761-767. (Pubitemid 35446628)
10. Fischer BE. Recombinant von Willebrand factor: potential therapeutic use. J Thromb Thrombolysis. 1999; 8(3): 197-205. (Pubitemid 29497773)
11. Turecek PL, Mitterer A, Matthiessen H.P., et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie. 2009; 29(SUPPL. 1):S32-S38.
12. Goudemand J, Parquet-Gernez A, Goudemand M. Purity of factor VIII concentrates. Blood Coagul Fibrinolysis. 1993; 4(3): 499-500.
13. Goudemand J, Scharrer I, Berntorp E., et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost. 2005; 3(10): 2219-2227. (Pubitemid 41727200)
14. Favaloro EJ, Lloyd J, Rowell J., et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [biostate and AHF (high purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Thromb Haemost. 2007; 97(6): 922-930. (Pubitemid 46939204)
15. Wichmann BA, Hill ID. Algorithm AS 183. An efficient and portable pseudo-random number generator. J R Stat Soc Ser C Appl Stat. 1982; 31(2): 188-190.
16. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949: 191-205.
17. Varadi K, Rottensteiner H, Gruber E., et al. Establishment of an automated VWF: RCo assay for measuring plasma samples with low activity [abstract]. J Thromb Haemost. 2011; 9(suppl 2): 919.
18. Kokame K, Nobe Y, Kokubo Y., Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005; 129(1): 93-100. (Pubitemid 40524057)
19. Kasper CK. Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation. Blood Coagul Fibrinolysis. 1991; 2(SUPPL. 1): 7-10.
20. Whelan SF, Hofbauer CJ, Horling F.M., et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013; 121(6): 1039-1048.
21. Schneppenheim R, Budde U, Krey S., et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost. 1996; 76(4): 598-602. (Pubitemid 26372017)
22. Mazurier C, Rodeghiero F; von Willebrand Factor Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Recommended abbreviations for von Willebrand Factor and its activities. Thromb Haemost. 2001; 86(2): 712. (Pubitemid 32743290)
23. Goodeve AC, Eikenboom JC, Ginsburg D, et al.; ISTH SSC Subcommittee on von Willebrand factor. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thromb Haemost. 2001; 85(5): 929-931. (Pubitemid 32421830)
24. Ewenstein BM. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia. 2001; 7(SUPPL. 1): 10-15. (Pubitemid 32184435)
25. Turecek PL, Schrenk G, Rottensteiner H., et al. Structure and function of a recombinant von Willebrand factor drug candidate. Semin Thromb Hemost. 2010; 36(5): 510-521.
26. Ewenstein BM, Collins P, Tarantino M.D., et al. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. Semin Hematol. 2004; 41(1 suppl 2): 1-16, discussion 16-18
27. Denis CV, Christophe OD, Oortwijn B.D., Lenting PJ. Clearance of von Willebrand factor. Thromb Haemost. 2008; 99(2): 271-278. (Pubitemid 351230955)
28. Fischer K, Pendu R, van Schooten CJ, et al. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE. 2009; 4(8):e6745.
29. Lenting PJ, Casari C, Christophe O.D., Denis CV. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012; 10(12): 2428-2437.
30. Vlot AJ, Koppelman SJ, Bouma B.N., Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost. 1998; 79(3): 456-465. (Pubitemid 28120774)
31. Cao W, Krishnaswamy S, Camire R.M., Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci USA. 2008; 105(21): 7416-7421. (Pubitemid 351830032)
32. Menache D, Aronson DL, Darr F, et al.; Cooperative Study Groups. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Br J Haematol. 1996; 94(4): 740-745. (Pubitemid 26308912)
33. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008; 112(1): 11-18.
34. Varadi K, Rottensteiner H, Vejda S., et al. Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor. J Thromb Haemost. 2009; 7(7): 1134-1142.
35. Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S., Müller HG, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia. 1998; 4(SUPPL. 3): 25-32. (Pubitemid 28561093)
36. Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem. 2010; 285(37): 28596-28603.
37. James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease [published online ahead of print January 7, 2013]. Blood.
38. Peake IR, Liddell MB, Moodie P, et al. Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood. 1990; 75(3): 654-661. (Pubitemid 20069205)
39. Mancuso DJ, Tuley EA, Castillo R, de Bosch N, Mannucci PM, Sadler JE. Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors. Thromb Haemost. 1994; 72(2): 180-185. (Pubitemid 24251276)
40. Shelton-Inloes B.B., Chehab FF, Mannucci P.M., Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest. 1987; 79(5): 1459-1465. (Pubitemid 17099650)
41. Surdhar GK, Enayat MS, Lawson S, Williams M.D., Hill FG. Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development. Blood. 2001; 98(1): 248-250.
42. Baronciani L, Cozzi G, Canciani M.T., et al. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost. 2000; 84(4): 536-540.
43. Baronciani L, Cozzi G, Canciani M.T., et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis. 2003; 30(3): 264-270. (Pubitemid 36539427)
44. Zanardelli S, Chion AC, Groot E, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood. 2009; 114(13): 2819-2828.
45. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost. 2002; 88(3): 378-379. (Pubitemid 35021592)